-

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16.

Tempus’ Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET. A live webcast of the conversation will be available here.

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus
Hanah Heintzelman
Hanah.heintzelman@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Tempus
Hanah Heintzelman
Hanah.heintzelman@tempus.com

More News From Tempus AI, Inc.

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. “The research that Tempus is presenting at this year’s AACR annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagn...

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus’ secure, AI-enabled physician portal. Because NC...

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy...
Back to Newsroom